By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arteriocyte, Inc. 

11000 Cedar Avenue

Cleveland  Ohio  44106  U.S.A.
Phone: 216-658-3970 Fax: 216-229-7323




Center for Stem Cell and Regenerative Medicine  (CSCRM startup company) is an early-stage company developing proprietary stem cell based therapies to grow new blood vessels for patients with a variety of vascular diseases.

Company News
Arteriocyte Announces Name Change To Compass Biomedical 12/12/2016 8:20:33 AM
Arteriocyte Divests Med Device Unit 11/28/2016 6:24:13 AM
Arteriocyte, Inc. Presents Its Update On Development Of Bioactive Coating To Maintain Tissue Viability In Acute Battlefield Injuries For The ACCSIL Bandage Program 10/25/2016 8:35:16 AM
Arteriocyte, Inc. Awarded FDA IDE Approval To Initiate Clinical Evaluation Of MAGELLAN® Bio-Bandage™ In Acute Deep Partial Thickness Thermal Injuries 5/2/2014 9:00:43 AM
Arteriocyte, Inc. Awarded BARDA Contract Valued up to $101.1 Million for Advanced Development of Arteriocyte's Magellan® BioBandage™ for Thermal Radiation Injury 9/26/2013 10:25:34 AM
Arteriocyte, Inc. Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors 1/31/2013 9:21:59 AM
National Institutes of Health (NIH) Awards Grant to Arteriocyte, Inc. and Its Collaboration With the University of Utah and Dana Farber to Develop Its NANEX™ Technology for Use in Bone Marrow Transplant 8/23/2012 10:45:16 AM
Arteriocyte, Inc. Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 4/4/2012 9:49:58 AM
Arteriocyte, Inc. Receives $1 Million Award From Ohio Third Frontier Program to Advance Its NANEX™ Technology Toward Clinical Use 7/20/2011 11:31:24 AM
Arteriocyte, Inc. and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 6/7/2011 11:28:35 AM